Clinical efficacy and safety of pembrolizumab and nivolumab in frontline treatment for classical Hodgkin lymphoma: systematic review and meta-analysis of clinical trials - Takeaways - MDSpire

Clinical efficacy and safety of pembrolizumab and nivolumab in frontline treatment for classical Hodgkin lymphoma: systematic review and meta-analysis of clinical trials

  • By

  • Artem Oganesyan

  • Andrew Gregory

  • Mark Gregory

  • Deivid Badalian

  • Asatur Chakmanyan

  • Lusine Harutyunyan

  • Vahe Khachatryan

  • Abhay Aradhya

  • Aheed Javaid

  • Yervand Hakobyan

  • Christian J Fidler

  • Pierluigi Porcu

  • June 26, 2026

  • 0 min

Share

  • 1

    This meta-analysis evaluates the efficacy and safety of pembrolizumab and nivolumab as first-line treatments for classical Hodgkin lymphoma.

  • 2

    Nine trials involving 880 patients with untreated classical Hodgkin lymphoma were analyzed, revealing an overall response rate of 86%.

  • 3

    The complete response rate was found to be 57%, with a 2-year progression-free survival rate of 90% and overall survival rate of 97%.

  • 4

    Forty-one percent of patients experienced grade ≥3 adverse events, with 17% experiencing grade ≥3 immune-related adverse events.

  • 5

    Nivolumab combined with brentuximab vedotin showed worse outcomes compared to AVD with pembrolizumab or nivolumab due to an older study population.

Original Source(s)

Clinical efficacy and safety of pembrolizumab and nivolumab in frontline treatment for classical Hodgkin lymphoma: systematic review and meta-analysis of clinical trials

  • by Artem Oganesyan, Andrew Gregory, Mark Gregory, Deivid Badalian, Asatur Chakmanyan, Lusine Harutyunyan, Vahe Khachatryan, Abhay Aradhya, Aheed Javaid, Yervand Hakobyan, Christian J Fidler, Pierluigi Porcu

  • June 26, 2026

Related Content

Metformin inhibits small intestinal neuroendocrine tumor growth in vivo

Attitudes and dilemmas facing fertility preservation decision-making by oncology patients from the perspective of healthcare professionals: a qualitative study

Tumor-driven stabilization of CD8+ T cell exhaustion and implications for cancer immunotherapy